Skip to main content

Advertisement

SpringerLink
Log in

Novel biomarkers to assess the risk for acute coronary syndrome: beyond troponins

  • IM - REVIEW
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

Abstract

Current diagnostic biomarkers for ACS are mainly represented by troponin I and troponin T. Dosing of these two molecules often leads to false positive results, since their plasma levels can increase in several different systemic settings. Therefore, identification of new markers able to detect patients with acute coronary syndromes is an emerging priority. On this view, many studies have been performed on different microRNAs, mitochondrial peptides, inflammatory cytokines and adhesion molecules with very promising results. Besides their introduction in screening programs, further studies are now needed in the acute setting, beyond or in association with troponin levels. This will help to better discriminate the real occurrence of an ACS in many patients accessing the emergency department for chest pain.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Velle-Forbord T et al (2019) Circulating microRNAs as predictive biomarkers of myocardial infarction: evidence from the HUNT study. Atherosclerosis. https://doi.org/10.1016/j.atherosclerosis.2019.07.024

    Article  PubMed  Google Scholar 

  2. Long B, Long DA, Tannenbaum L, Koyfman A (2019) An emergency medicine approach to troponin elevation due to causes other than occlusion myocardial infarction. Am J Emerg Med. https://doi.org/10.1016/j.ajem.2019.12.007

    Article  PubMed  Google Scholar 

  3. Roffi M et al (2016) 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. https://doi.org/10.1093/eurheartj/ehv320

    Article  PubMed  Google Scholar 

  4. Gilardi E, Iacomini P, Marsiliani D, De Marco G, Covino M (2014) Biomarkers in the prediction and management of acute coronary syndromes: current perspectives. Res Reports Clin Cardiol. https://doi.org/10.2147/rrcc.s36294

    Article  Google Scholar 

  5. Wang X et al (2013) Increased expression of microRNA-146a decreases myocardial ischaemia/reperfusion injury. Cardiovasc Res. https://doi.org/10.1093/cvr/cvs356

    Article  PubMed  PubMed Central  Google Scholar 

  6. Raitoharju E et al (2011) MiR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques in the Tampere vascular study. Atherosclerosis. https://doi.org/10.1016/j.atherosclerosis.2011.07.020

    Article  PubMed  Google Scholar 

  7. Xue S et al (2019) Circulating miR-26a-1, miR-146a and miR-199a-1 are potential candidate biomarkers for acute myocardial infarction. Mol Med 25:1–12

    Article  CAS  Google Scholar 

  8. Chiang MH et al (2020) miR-26a attenuates cardiac apoptosis and fibrosis by targeting ataxia–telangiectasia mutated in myocardial infarction. J Cell Physiol. https://doi.org/10.1002/jcp.29537

    Article  PubMed  Google Scholar 

  9. Wang J et al (2014) miR-499 protects cardiomyocytes from H2O2-induced apoptosis via its effects on Pdcd4 and Pacs2. RNA Biol. https://doi.org/10.4161/rna.28300

    Article  PubMed  PubMed Central  Google Scholar 

  10. Zhang YH, He K, Shi G (2017) Effects of microRNA-499 on the inflammatory damage of endothelial cells during coronary artery disease via the targeting of PDCD4 through the NF-Κβ/TNF-α signaling pathway. Cell Physiol Biochem. https://doi.org/10.1159/000484588

    Article  PubMed  PubMed Central  Google Scholar 

  11. Bernardo BC et al (2012) Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. Proc Natl Acad Sci USA. https://doi.org/10.1073/pnas.1206432109

    Article  PubMed  Google Scholar 

  12. Boon RA et al (2013) MicroRNA-34a regulates cardiac ageing and function. Nature. https://doi.org/10.1038/nature11919

    Article  PubMed  Google Scholar 

  13. Kumar D et al (2020) Circulatory miR-133b and miR-21 as novel biomarkers in early prediction and diagnosis of coronary artery disease. Genes (Basel) 11(2):164

    Article  CAS  Google Scholar 

  14. Gigante B et al (2020) MicroRNA signatures predict early major coronary events in middle-aged men and women. Cell Death Dis 11:10–12

    Article  Google Scholar 

  15. Chen Y, Ye X, Yan F (2019) MicroRNA 3113-5p is a novel marker for early cardiac ischemia/reperfusion injury. Diagn Pathol. https://doi.org/10.1186/s13000-019-0894-1

    Article  PubMed  PubMed Central  Google Scholar 

  16. Aurora AB et al (2012) MicroRNA-214 protects the mouse heart from ischemic injury by controlling Ca2+ overload and cell death. J Clin Invest. https://doi.org/10.1172/JCI59327

    Article  PubMed  PubMed Central  Google Scholar 

  17. Hullinger TG et al (2012) Inhibition of miR-15 protects against cardiac ischemic injury. Circ Res. https://doi.org/10.1161/CIRCRESAHA.111.244442

    Article  PubMed  Google Scholar 

  18. Yang Y et al (2015) Plasma long non-coding RNA, CoroMarker, a novel biomarker for diagnosis of coronary artery disease. Clin Sci. https://doi.org/10.1042/CS20150121

    Article  PubMed  PubMed Central  Google Scholar 

  19. Li M et al (2018) Circulating long noncoding RNA LIPCAR acts as a novel biomarker in patients with ST-segment elevation myocardial infarction. Med Sci Monit. https://doi.org/10.12659/MSM.909348

    Article  PubMed  PubMed Central  Google Scholar 

  20. Lee C, Kim KH, Cohen P (2016) MOTS-c: a novel mitochondrial-derived peptide regulating muscle and fat metabolism. Free Radical Biol Med. https://doi.org/10.1016/j.freeradbiomed.2016.05.015

    Article  Google Scholar 

  21. Qin Q et al (2018) Downregulation of circulating MOTS-c levels in patients with coronary endothelial dysfunction. Int J Cardiol. https://doi.org/10.1016/j.ijcard.2017.12.001

    Article  PubMed  Google Scholar 

  22. Yang Y et al (2019) The role of mitochondria-derived peptides in cardiovascular disease: recent updates. Biomed Pharmacother 117:109075

    Article  CAS  Google Scholar 

  23. Yen K, Lee C, Mehta H, Cohen P (2012) The emerging role of the mitochondrial-derived peptide humanin in stress resistance. J Mol Endocrinol. https://doi.org/10.1530/JME-12-0203

    Article  Google Scholar 

  24. Muzumdar RH et al (2010) Acute humanin therapy attenuates myocardial ischemia and reperfusion injury in mice. Arterioscler Thromb Vasc Biol. https://doi.org/10.1161/ATVBAHA.110.205997

    Article  PubMed  PubMed Central  Google Scholar 

  25. Hashimoto Y, Kurita M, Aiso S, Nishimoto I, Matsuoka M (2009) Humanin inhibits neuronal cell death by interacting with a cytokine receptor complex or complexes involving CNTF receptor α/WSX-1/gp130. Mol Biol Cell. https://doi.org/10.1091/mbc.E09-02-0168

    Article  PubMed  PubMed Central  Google Scholar 

  26. Lee C, Yen K, Cohen P (2013) Humanin: a harbinger of mitochondrial-derived peptides? Trends Endocrinol Metab. https://doi.org/10.1016/j.tem.2013.01.005

    Article  PubMed  PubMed Central  Google Scholar 

  27. Widmer RJ et al (2013) Circulating humanin levels are associated with preserved coronary endothelial function. Am J Physiol Heart Circ Physiol 304(3):H393–H397

    Article  CAS  Google Scholar 

  28. Thummasorn S, Shinlapawittayatorn K, Chattipakorn SC, Chattipakorn N (2017) High-dose Humanin analogue applied during ischemia exerts cardioprotection against ischemia/reperfusion injury by reducing mitochondrial dysfunction. Cardiovasc Ther. https://doi.org/10.1111/1755-5922.12289

    Article  PubMed  Google Scholar 

  29. Liang J et al (2009) Myeloperoxidase (MPO) and interleukin-17 (IL-17) plasma levels are increased in patients with acute coronary syndromes. J Int Med Res. https://doi.org/10.1177/147323000903700331

    Article  PubMed  Google Scholar 

  30. Ávalos AM et al (2012) IL-17A levels increase in the infarcted region of the left ventricle in a rat model of myocardial infarction. Biol Res. https://doi.org/10.4067/S0716-97602012000200012

    Article  PubMed  Google Scholar 

  31. Liao YH et al (2012) Interleukin-17A contributes to myocardial ischemia/reperfusion injury by regulating cardiomyocyte apoptosis and neutrophil infiltration. J Am Coll Cardiol. https://doi.org/10.1016/j.jacc.2011.10.863

    Article  PubMed  PubMed Central  Google Scholar 

  32. Xu Y et al (2020) The expression of interleukin-25 increases in human coronary artery disease and is associated with the severity of coronary stenosis. Anatol J Cardiol 23:151–159

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Tajfard M et al (2017) Serum concentrations of MCP-1 and IL-6 in combination predict the presence of coronary artery disease and mortality in subjects undergoing coronary angiography. Mol Cell Biochem 435:37–45

    Article  CAS  Google Scholar 

  34. Ridker PM et al (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. https://doi.org/10.1056/NEJMoa1707914

    Article  PubMed  Google Scholar 

  35. Schofer N, Ludwig S, Rübsamen N, Schnabel R, Lackner KJ, Ruprecht HJ, Bickel C, Landmesser U, Blankenberg S, Zeller T (2018) Prognostic impact of interleukin-1 receptor antagonist in patients with documented coronary artery disease. Int J Cardiol. 257:24–29

    Article  Google Scholar 

  36. Buckley LF, Abbate A (2018) Interleukin-1 blockade in cardiovascular diseases: from bench to bedside. Bio Drugs 32:111–118

    CAS  Google Scholar 

  37. Zheng Z-H, Zeng X, Nie X-Y, Cheng Y-J, Liu J, Lin X-X, Yao H, Ji C-C, Chen X-M, Jun F, Su-Hua Wu (2019) Interleukin-1 blockade treatment decreasing cardiovascular risk. Clin Cardiol 42:942–951

    Article  Google Scholar 

  38. Herder C, Heras Gala TL, Carstensen-Kirberg M, Huth C, Zierer A, Wahl S, Sudduth-Klinger J, Kuulasmaa K, Peretz D, Ligthart S, Bongaerts BWC, Dehghan A, Arfan Ikram M, Jula A, Kee F, Pietilä A, Saarela O, Zeller T, Blankenberg S, Meisinger C, Peters A, Roden M, Salomaa V, Koenig W, Thorand B (2017) Circulating levels of interleukin 1-receptor antagonist and risk of cardiovascular disease: meta-analysis of six population-based cohorts. Arterioscler Thromb Vasc Biol. 37:1222–1227

    Article  CAS  Google Scholar 

  39. Hjort M, Eggers KM, Lindhagen L, Agewall S, Brolin EB, Collste O, Daniel M, Ekenbäck C, Frick M, Henareh L, Hofman-Bang C, Malmqvist K, Spaak J, Sörensson P, Hassan SY, Tornvall P, Lindahl B (2019) Increased inflammatory activity in patients 3 months after myocardial infarction with nonobstructive coronary arteries. Clin Chem. 65:1023–1030

    Article  CAS  Google Scholar 

  40. Qian W, Zhao C, Li D, Dai R (2018) Mechanism of interleukin-1 receptor antagonist protection against myocardial ischaemia/reperfusion-induced injury. Arch Cardiovasc Dis 111:545–554

    Article  Google Scholar 

  41. Hulok A et al (2014) Soluble cell adhesion molecules—does estimating sVCAM-1 and sICAM-1 concentration provide additional information about cardiovascular risk in patients with coronary artery disease? Adv Clin Exp Med 23:735–741

    Article  Google Scholar 

  42. Liu A, Wan A, Feng A, Rui R, Zhou B (2018) ICAM-1 gene rs5498 polymorphism decreases the risk of coronary artery disease. Medicine (United States). https://doi.org/10.1097/MD.0000000000012523

    Article  PubMed  PubMed Central  Google Scholar 

  43. Yin DL et al (2019) Association between the ICAM-1 gene polymorphism and coronary heart disease risk: a meta-analysis. Biosci Rep 39:1–7

    Google Scholar 

  44. Wang Y et al (2019) The role of OX40L and ICAM-1 in the stability of coronary atherosclerotic plaques and their relationship with sudden coronary death. BMC Cardiovasc Disord. https://doi.org/10.1186/s12872-019-1251-8

    Article  PubMed  PubMed Central  Google Scholar 

  45. Radecke CE et al (2015) Coronary artery endothelial cells and microparticles increase expression of VCAM-1 in myocardial infarction. Thromb Haemost. https://doi.org/10.1160/TH14-02-0151

    Article  PubMed  Google Scholar 

  46. Dos Santos JC et al (2018) Relationship between circulating VCAM-1, ICAM-1, E-selectin and MMP9 and the extent of coronary lesions. Clinics. https://doi.org/10.6061/clinics/2018/e203

    Article  PubMed  PubMed Central  Google Scholar 

  47. Ambros V (2004) The functions of animal microRNAs. Nature 431:350–355

    Article  CAS  Google Scholar 

  48. Cheng Y et al (2010) A translational study of circulating cell-free microRNA-1 in acute myocardial infarction. Clin Sci. https://doi.org/10.1042/CS20090645

    Article  PubMed  PubMed Central  Google Scholar 

  49. Dong S et al (2009) MicroRNA expression signature and the role of MicroRNA-21 in the early phase of acute myocardial infarction. J Biol Chem. https://doi.org/10.1074/jbc.M109.027896

    Article  PubMed  PubMed Central  Google Scholar 

  50. Iaconetti C, Gareri C, Polimeni A, Indolfi C (2013) Non-coding RNAs: the ‘dark matter’ of cardiovascular pathophysiology. Int J Mol Sci. https://doi.org/10.3390/ijms141019987

    Article  PubMed  PubMed Central  Google Scholar 

  51. Ren J et al (2013) Signature of circulating MicroRNAs as potential biomarkers in vulnerable coronary artery disease. PLoS ONE. https://doi.org/10.1371/journal.pone.0080738

    Article  PubMed  PubMed Central  Google Scholar 

  52. De Rosa S, Curcio A, Indolfi C (2014) Emerging role of micrornas in cardiovascular diseases. Circ J 78:567–575

    Article  Google Scholar 

  53. Islas JF, Moreno-Cuevas JE (2018) A microRNA perspective on cardiovascular development and diseases: an update. Int J Mol Sci. https://doi.org/10.3390/ijms19072075

    Article  PubMed  PubMed Central  Google Scholar 

  54. Sun T et al (2017) The role of microRNAs in myocardial infarction: from molecular mechanism to clinical application. Int J Mol Sci. https://doi.org/10.3390/ijms18040745

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Emergency Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Largo A. Gemelli, 8, 00168, Rome, Italy

    Andrea Piccioni, Federico Valletta, Christian Zanza, Alessandra Esperide & Francesco Franceschi

Authors
  1. Andrea Piccioni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Federico Valletta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christian Zanza
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alessandra Esperide
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Francesco Franceschi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrea Piccioni.

Ethics declarations

Conflict of interest

No conflict of interest.

Statement of human and animal rights

Not applicable.

Informed consent

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Piccioni, A., Valletta, F., Zanza, C. et al. Novel biomarkers to assess the risk for acute coronary syndrome: beyond troponins. Intern Emerg Med 15, 1193–1199 (2020). https://doi.org/10.1007/s11739-020-02422-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11739-020-02422-z

Keywords

Search

Navigation